Home > Products > HS-388 011

Histone3.3 G34V antibody - HS-388 011 K.O.

Histone 3.3 G34V is a driver mutation in paediatric glioblastoma
Mouse monoclonal purified IgG
Cat. No.: HS-388 011
Amount: 100 µg
Price: $415.00
Cat. No. HS-388 011 100 µg purified IgG, lyophilized. Azide was added before lyophilization. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications
 
WB: not recommended
IP: not tested yet
ICC: not tested yet
IHC: not tested yet
IHC-P: 1 : 1000 up to 1 : 2000 gallery  
ChIP: yes
Clone 329E5
Subtype IgG2b
Immunogen Synthetic peptide corresponding to AA 29 to 38 from human H3F3A G34V (UniProt Id: P84243)
Reactivity Reacts with: human (P84243).
Other species not tested yet.
Specificity Specific for the H3.3 G34V mutant. Negligible cross-reactivity to H3.3 G34R, and no cross-reactivity to unmutated H3.3. K.O. validated
Data sheet hs-388_011.pdf

References for Histone3.3 G34V - HS-388 011

Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas.
Gianno F, Antonelli M, Di Dio T, Minasi S, Donofrio V, Buccoliero AM, Gardiman MP, Pollo B, Diomedi Camassei F, Rossi S, Novello M, et al.
The American journal of surgical pathology (2021) 452: 200-204. HS-388 011 IHC-P; tested species: human
Cat. No.: HS-388 011
Amount: 100 µg
Price: $415.00

H3.3 G34V mutation detection in xenograft model of pedriatic high-grade glioma

Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas.
Gianno F, Antonelli M, Di Dio T, Minasi S, Donofrio V, Buccoliero AM, Gardiman MP, Pollo B, Diomedi Camassei F, Rossi S, Novello M, et al.
The American journal of surgical pathology (2021) 452: 200-204. HS-388 011 IHC-P; tested species: human
IHC-P
IHC-P
Background
The gene mutations H3.3 G34V and H3.3 G34R of histone 3.3 (H3.3 or H3F3A) have been recently identified as driver mutations in paediatric glioblastoma. G34V/R mutations are restricted to tumors of the cerebral hemispheres and are most prevalent in adolescents and young adults. These mutations cause profound upregulation of MYCN, a potent oncogene. Emerging evidence strongly suggests that paediatric glioblastomas with H3F3A mutations can be subclassified into distinct entities.

This antibody is part of the HistoSure® product line, specifically developed and tested for human pathology.